arrow
M

Maria Esposito

University of L'Aquila
H指数:28
被引数:3,350

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis)

52周内布达拉木单抗在患者层面的累积临床获益:一项多中心真实世界研究-IL PSO(意大利银屑病全景)

2026-09-170
OAAI
Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study

非节段性白癜风患者外用鲁索利替尼的实世界有效性:一项860例患者多中心研究中关于复色、心理健康和生活质量结局的研究

2026-08-170
PRE
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area

从度普利单抗转换至lebrikizumab治疗涉及头颈区域的轻中度特应性皮炎的疗效结局

2026-07-220
OAAI
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)

Dupilumab或Upadacitinib在轻至重度特应性皮炎中的纵向反应轨迹:一项多中心真实世界研究:IL-AD(意大利特应性皮炎研究)

2026-05-290
OAAI
Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study—IL PSO (Italian Landscape PSOriasis)

比mekizumab对掌跖银屑病的疗效:一项16周的多中心回顾性研究—IL PSO(意大利银屑病景观)

2026-05-280
OAAI
Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN Study

度普利尤单抗治疗结节性痒疹:DUPItaPN研究104周真实世界结局

2026-04-150
OA
Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study

特应性皮炎患者接受度普利尤单抗或特拉利尤单抗治疗时的银屑病和血清阴性脊柱关节病:一项多中心观察性研究

2026-02-011
PRE
Tirbanibulin 1% real-world use in 679 actinic keratoses patients during warm season (SUMM-AK study)

Tirbanibulin 1%在温暖季节(SUMM-AK研究)中679例光线性角化病患者中的真实世界应用

2025-11-260
OAAI
Survival; trust; and compassion: persistent HIV prevention concerns faced by Black sexual and gender minority communities in the US South – a qualitative study

生存;信任;以及同情心:美国南部黑人性取向与性别少数群体面临的持续性艾滋病预防问题——一项定性研究

2025-11-180
OAAI
Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors

巴瑞替尼治疗成人特应性皮炎:真实世界疗效、安全性及应答预测因子

2025-11-030
OAAI
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study

有效性、安全性及与健康相关的生活质量:接受Lebrikizumab治疗的轻中度特应性皮炎的16周全国性回顾性队列研究

2025-10-100
OA
Long-Term Persistence with Guselkumab: A 5-Year Multicenter Retrospective Study across 14 Dermatology Centers in Italy

guselkumab的长期持续性:一项在意大利14个皮肤病学中心进行的为期5年的多中心回顾性研究

2025-10-010
OAAI
Elective First-Line Use of Dimethyl Fumarate in Psoriasis: Insights from an Italian Cohort

二甲酸富马酸在银屑病中的选择性一线应用:来自意大利队列的见解

2025-10-010
OAAI
Brodalumab Efficacy in Psoriasis Patients with Inadequate Response to IL-23 or IL-12/23 Inhibitors: Multicenter Italian Retrospective Analysis-IL PSO (Italian Landscape Psoriasis)

Brodalumab在对抗IL-23或IL-12/23抑制剂反应不足的银屑病患者中的疗效:多中心意大利回顾性分析-IL PSO(意大利银屑病全景)

2025-10-010
OAAI
The evaluation of effectiveness of IL-17 and IL-23 inhibitors on nail and enthesis involvement in early psoriatic arthritis patients by high-frequency ultrasonography: a single-centre prospective proof-of-concept study

通过高频超声评估IL-17和IL-23抑制剂对早期银屑病关节炎患者甲和肌腱附着点受累的有效性:一项单中心前瞻性概念验证研究

2025-09-180
OAAI
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study

银屑病患者中 guselkumab 的长期真实世界有效性与药物生存率:一项为期5年的回顾性研究

2025-09-160
OA
Assessment of gene signatures following the inhibition of IL-23: a study to evaluate the mechanistic effects behind the clinical efficacy of guselkumab in patients with psoriatic arthritis

IL-23抑制后基因特征的评价:一项评估guselkumab在银屑病关节炎患者中临床疗效背后机制效应的研究

2025-09-020
OA